These observations collectively suggest the existence of a Dectin-1–PGE2–IL-22BP axis that modulates intestinal tumorigenesis, thereby positioning Dectin-1 as a potential therapeutic target for CRC (88). The gene discussed is IL22RA2; the disease is colorectal carcinoma.